생화학분자생물학회입니다.
Current status and prospects of the organoid based regenerative medicine
작성자
Jongman Yoo작성일자
2022-12-22조회수
1074Name: Jongman Yoo ( jongmanyoo@cha.ac.kr ) | ||
2020~present | Associate Professor, School of Medicine, CHA University, Korea | |
2018~present | Chief Executive Officer, ORGANOIDSCIENCES Ltd. | |
2015-2020 | Assistant Professor, School of Medicine, CHA University, Korea | |
2014-2015 | Instructor, College of Medicine, Yonsei University, Korea | |
2007-2014 | M.D, Ph.D, in Medicine, CHA University, Korea | |
1998-2004 | B.S, in Life Science, Korea University, Korea |
Current status and prospects of the organoid based regenerative medicine
Organoids derived from stem cells or organ-specific progenitors are self-organizable, self-renewable, and multicellular three-dimensional (3D) structures that can mimic the function and structure of the derived tissue. Due to such characteristics, organoids are attracting attention as an excellent ex vivo model for drug screening at the stage of drug development. In addition, since the applicability of organoids as therapeutics for tissue regeneration has been embossed, the development of various organoids-based regenerative medicine has been rapidly progressing, reaching the clinical trial stage. In this review, we give a general overview of organoids and describe current status and prospects of organoid-based regenerative medicine, focusing on organoid-based regenerative therapeutics currently under development including clinical trials.
BMB Rep. 2022 Dec 16;5808. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/36523211/